Core Viewpoint - The recent prescription of Palopegteriparatide at a hospital in Hainan marks a significant milestone for the company in the endocrine innovation field, with the drug being the first and only parathyroid hormone replacement therapy globally [1][2]. Group 1: Company Developments - The stock of Viesheng Pharmaceutical (02561) rose by 4.68%, reaching HKD 39.8 [1]. - The CEO of Viesheng Pharmaceutical highlighted the importance of the first prescription of Palopegteriparatide as a step towards innovation in the endocrine sector [1]. - The company is committed to accelerating the domestic approval process for Palopegteriparatide and continuing its focus on innovative endocrine therapies [1]. Group 2: Product Pipeline - The company is advancing its long-acting growth hormone, Long-acting Growth Hormone, which is expected to be approved for domestic use in the second half of 2025, potentially becoming the third long-acting growth hormone in China [2]. - Viesheng Pharmaceutical has two unique products, namely Navepeptide and Palopegteriparatide, with the latter expected to submit a market application by the end of 2025 [2]. - Collaborations with WuXi Biologics and Anke Bio are in place to enhance local production and commercialize products, indicating a promising market outlook [2].
维昇药业-B涨超4% 帕罗培特立帕肽近期在博鳌完成首例处方